Karyopharm Therapeutics' Q3 net loss widens

Karyopharm Therapeutics

03/11/2025 12:11

Overview

Karyopharm Q3 total revenue rises to $44 mln, driven by XPOVIO sales growth

Net loss for Q3 2025 was $33.1 mln, slightly higher than last year

Company reaffirms full-year 2025 revenue guidance of $140 mln to $155 mln

Outlook

Karyopharm reaffirms 2025 total revenue guidance of $140 mln to $155 mln

Company expects 2025 U.S. XPOVIO revenue of $110 mln to $120 mln

Karyopharm lowers 2025 R&D and SG&A expenses to $235 mln to $245 mln

Result Drivers

XPOVIO SALES - U.S. net product revenue for XPOVIO increased by 8.5% compared to Q3 2024, driven by consistent demand in the community setting

GLOBAL ACCESS - Expanded global patient access for selinexor led to growth in royalty revenue from international partners

LICENSE REVENUE - Increase in license and other revenue was driven by milestone-related revenue from Menarini

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$32.03 mln
Q3 Net Income
-$33.12 mln
Q3 Operating Expenses
$59.26 mln
Q3 Operating Income
-$15.22 mln


Press Release: ID:nPn8W7ycsa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)